Milestones are at the core of the current system designed to evaluate medical residency and fellowship programs and their participants. But are all milestones meaningful for medical education? This idea was at the center of a debate during the 2017 ACR/ARHP Annual Meeting, during which speakers explored the advantages and drawbacks of using training milestones for rheumatology fellowships…
Articles by Natasha Yetman
U.S. Telehealth Industry Eyes Medicare for Its Next Big Check
(Reuters)—After years of lobbying in Washington, U.S. telehealth providers have the first hints that the dam could break on public funding for an industry they say could save taxpayers billions. Four bills that could be signed into law over the next year carry the solutions to barriers that have prevented the U.S.s’ huge over-65 health…
Amazon, Berkshire, JPMorgan Partner to Cut U.S. Healthcare Costs
NEW YORK (Reuters)—Amazon.com Inc., Berkshire Hathaway Inc. and JPMorgan Chase & Co. said on Tuesday they will form a company to cut health costs for hundreds of thousands of their employees, setting up a major challenge to an inefficient U.S. healthcare system. The move by three of the best-known U.S. business leaders—Amazon’s Jeff Bezos, Berkshire’s…
Synthetic DMARDs May Blunt Pneumococcal Vaccine Response in Systemic Sclerosis
NEW YORK (Reuters Health)—Pneumococcal vaccination yields a satisfactory antibody response in patients with systemic sclerosis (SSc), but synthetic disease-modifying antirheumatic drugs (DMARDs) might reduce the vaccine response in these individuals, according to a report from Sweden. The prospective study, published online Jan. 8 in Rheumatology, evaluated the response to either pneumococcal conjugate vaccine (PCV13) or…
U.S. Appeals Court Invalidates J&J Patent on Remicade
(Reuters)—A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug, Remicade (infliximab), limiting J&J’s ability to seek damages from Pfizer Inc. over its launch of a lower-cost version of the drug. The U.S. Circuit Court of Appeals for the Federal Circuit affirmed…
U.S. Lets More Healthcare Workers Prescribe Opioid Addiction Treatment
WASHINGTON (Reuters)—The U.S. Drug Enforcement Administration said on Tuesday it had changed a regulation to allow more healthcare professionals to prescribe a medication used to treat opioid addiction, opening up access in rural America where there are few doctors.1 Prior to 2000, only physicians could treat those with opioid addiction and had to register with…
Delaware Sues Opioid Manufacturers, Distributors Over Epidemic
(Reuters)—Delaware on Friday became the latest state to file a lawsuit accusing corporations of helping fuel the national opioid epidemic, suing a wide range of companies involved in making, distributing and selling prescription painkillers.1 The lawsuit, filed by Delaware Attorney General Matt Denn in a state court, targeted drugmakers Purdue Pharma LP and Endo International…
Use Epidural Steroid Injections Cautiously in Patients with Fracture Risk
NEW YORK (Reuters Health)—Use of epidural steroid injections (ESIs) “should be approached with prudence,” particularly in patients who are at risk for osteoporotic fractures, such as women of postmenopausal age, according to authors of a systematic review. Although the literature presents a mixed picture, ESIs in doses as low as 80 mg methylprednisolone equivalents seem…
Kentucky Accuses McKesson of Helping Fuel the Opioid Epidemic
(Reuters)—Kentucky’s attorney general on Monday accused drug distributor McKesson Corp. of helping fuel the opioid epidemic by failing to halt shipments of suspiciously large or frequent orders by pharmacies of prescription painkillers. The complaint by Kentucky Attorney General Andy Beshear was filed in a state court and was one of a flurry of lawsuits by…
Biosimilars: Still Waiting for Promise to Materialize
During the 2017 ACR/ARHP Annual Meeting, advances in biosimilar treatments were abuzz. However, many speakers noted that the presence of biosimilars on the market has not yet resulted in greater access to treatment and lower drug pricing in the U.S…
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 97
- Next Page »